Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | CRHBP | P24387 | 1/20 | 0.57 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.57 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24038945 | 0.90 | — | — | |
| SCHEMBL26928719 | 0.86 | ALDH1A1 (0.55) | MEN1KMT2AHTTALDH1A1CRHBP | |
| SCHEMBL16684401 | 0.82 | MEN1 (0.47) | MEN1KMT2AHTTALDH1A1CRHBP | |
| SCHEMBL5105057 | 0.80 | ALDH1A1 (0.50) | MEN1KMT2AALDH1A1KDM4EP2RX7 | |
| SCHEMBL5092050 | 0.78 | ALDH1A1 (0.49) | MEN1KMT2AHTTALDH1A1CRHBP | |
| SCHEMBL14382347 | 0.78 | ALDH1A1 (0.49) | MEN1KMT2AHTTALDH1A1CRHBP | |
| SCHEMBL31053476 | 0.78 | HTT (0.53) | MEN1KMT2AHTTALDH1A1CRHBP | |
| SCHEMBL28289553 | 0.78 | ALDH1A1 (0.53) | MEN1KMT2AHTTALDH1A1CRHBP | |
| SCHEMBL5528066 | 0.77 | ALDH1A1 (0.42) | MEN1KMT2AHTTALDH1A1CRHBP | |
| SCHEMBL2841738 | 0.76 | THRB (0.63) | MEN1KMT2AHTTALDH1A1CRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996016982-A2 | ULTRASELECTIVE OPIOIDMIMETIC PEPTIDES AND PHARMACOLOGICAL AND THERAPEUTIC USES THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-06-06 | — | — | WO | claimed |
| CN-1040191-A | Parasiticidal N '-replacement-N-alkyl-carbonyl-N '-acylhydrazine and N '-replacement-N-acyl group-N '-alkyl-carbonyl hydrazine | ROHM & HAAS (US) | 1990-03-07 | — | — | CN | claimed |
| US-20250243161-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| CN-119822990-A | Adamantane isopropanolamine structure compound and preparation method and application thereof | 贵州大学 | 2025-04-15 | — | — | CN | disclosed |
| US-12269800-B2 | Delivery of therapeutic alkaloid compounds | SENSORIUM THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20250051277-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20240246910-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2024-07-25 | — | — | US | disclosed |
| US-11999694-B2 | Delivery of therapeutic alkaloid compounds | SENSORIUM THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20230322976-A1 | METHOD OF EVALUATING DEGREE OF PURITY OF PHARMACEUTICAL SUBSTANCE CONTAINED IN COMPOSITE BODY, AND METHOD OF PRODUCING COMPOSITE BODY | BIODYNAMIC RESEARCH FOUNDATION (JP) | 2023-10-12 | — | — | US | disclosed |
| CN-113999222-B | Adamantyl oxadiazole-containing compound and preparation method and application thereof | 贵州大学 | 2023-06-27 | — | — | CN | disclosed |
| EP-4190824-A1 | METHOD FOR EVALUATING DEGREE OF PURITY OF PHARMACEUTICAL SUBSTANCE CONTAINED IN COMPOSITE BODY, AND METHOD FOR PRODUCING COMPOSITE BODY | Toray Industries, Inc. (JP) | 2023-06-07 | — | — | EP | disclosed |
| WO-2003075660-A1 | METHOD OF TREATMENT OR PREVENTION OF OBESITY | MERCK & CO., INC. (US) | 2003-09-18 | — | — | WO | disclosed |
| WO-2003065983-A2 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK & CO., INC. (US) | 2003-08-14 | — | — | WO | disclosed |
| EP-0934283-A2 | ARTHROPODICIDAL AND FUNGICIDAL CYCLIC AMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-08-11 | — | — | EP | disclosed |
| US-5780589-A | DIPEPTIDES, TRIPEPTIDES OR CYCLIC PEPTIDES AS ANTAGONIST OF OPIOID RECEPTORS TREATING DRUG ABUSE, DRUG DEPENDENCE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1998005652-A2 | ARTHROPODICIDAL AND FUNGICIDAL CYCLIC AMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-02-12 | — | — | WO | disclosed |
| WO-1996016982-A2 | ULTRASELECTIVE OPIOIDMIMETIC PEPTIDES AND PHARMACOLOGICAL AND THERAPEUTIC USES THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-06-06 | — | — | WO | disclosed |
| WO-1993000359-A1 | MODIFIED PEPTIDES TRANSPORTABLE INTO THE CENTRAL NERVOUS SYSTEM | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-01-07 | — | — | WO | disclosed |
| US-4097599-A | PESTICIDES | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION (AU) | 1978-06-27 | — | — | US | disclosed |
| US-4038405-A | MITICIDES | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION (AU) | 1977-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051277-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | MEN1 163/4885KMT2A 2128/4885HTT 2860/4885 |
| US-20250243161-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | MEN1 163/4885KMT2A 2128/4885HTT 2860/4885 |
| US-20240246910-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | MEN1 163/4885KMT2A 2128/4885HTT 2860/4885 |
| US-12269800-B2 | Delivery of therapeutic alkaloid compounds | PNMT, HNMT, NNMT | MEN1 163/4885KMT2A 2128/4885HTT 2860/4885 |
| US-11999694-B2 | Delivery of therapeutic alkaloid compounds | PNMT, HNMT, NNMT | MEN1 163/4885KMT2A 2128/4885HTT 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.